Skip to main content
main-content

01.03.2018 | Novel and Emerging Risk Factors (K Nasir, Section Editor) | Ausgabe 3/2018

Current Cardiovascular Risk Reports 3/2018

Novel and Emerging Biomarkers with Risk Predictive Utility for Atherosclerotic Cardiovascular Disease

Zeitschrift:
Current Cardiovascular Risk Reports > Ausgabe 3/2018
Autoren:
Nimish N. Shah, Anand Rohatgi
Wichtige Hinweise
This article is part of the Topical Collection on Novel and Emerging Risk Factors

Abstract

Purpose of Review

Since the release of the American Heart Association and American College of Cardiology’s 2013 pooled cohort equations and the European Cardiology Society’s 2016 SCORE, numerous studies have better characterized the predictive ability of emerging and novel biomarkers for atherosclerotic cardiovascular disease (ASCVD). Here, we review these emerging ASCVD biomarkers, with a focus on those that have been assessed using risk discrimination and reclassification performance indices in large population studies.

Recent Findings

These biomarkers include genetic risk scores (GRS) based on a growing number of risk alleles, inflammatory and thrombotic markers, lipid components and functional measures, protein metabolites, microRNAs, and a variety of subclinical atherosclerosis imaging measures. While most of these markers have demonstrated some degree of association with and predictive utility for ASCVD, only coronary artery calcium (CAC) has demonstrated consistent risk prediction improvement across multiple population and risk profiles.

Summary

Although CAC has garnered evidence to merit inclusion in modern risk prediction algorithms, large population studies and high-throughput genetic and protein technologies have shown promise for the risk prediction utility of several emerging biomarkers that may warrant consideration in future multimodality ASCVD risk prediction algorithms.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise